Biomind Labs Inc. announced that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries. This innovative technology, designed by the scientific team, has the potential to provide new levels of safety for both the patients and also the physicians who will be prescribing these medications. The company view this technology as marking a new concept within the psychedelic industry to increase the quality of treatments while ensuring their traceability. The objective is to provide the confidence that health agencies and government authorities require to start supporting this disruptive way of treating conditions such as depression, anxiety, addictive disorders, eating disorders and chronic pain, among others.